HPV (İnsan papillomavirus) aşısına güncel yaklaşımlar

Year 2024, Volume: 4 Issue: 1, 18 - 23, 30.06.2024

Özlem Dal , Leman Gafarlı , Melek İpek Karagöz , Ayşe Nur Çakır Güngör

Abstract

İnsan papilloma virüs (HPV) dünyada en sık cinsel yolla bulaşan hastalık olarak kabul edilmektedir. HPV enfeksiyonu yaygın siğillere ve diğer dermatolojik olmayan hastalıklara sebep olur. Onkojenik (yüksek riskli) HPV suşları ve serviks kanseri arasındaki ilişki ise açıkça ortaya konulmuştur. HPV aşıları, kanser ilişkili HPV enfeksiyonlarına karşı uzun süre ve güvenilir bir koruma sağlar. Ayrıca HPV aşılaması, HPV’nin sebep olduğu serviks dışı kanserlerin gelişim riskini de azaltır. Aşı, doğal maruziyetten önce enfeksiyonları engelleyerek etki gösterir. Bu yüzden faydalarını en üst düzeye çıkarmak için HPV aşısının cinsel aktivite başlamadan önce yapılması önerilir. HPV ve aşı konusunda eğitim vermek özellikle düşük ve orta gelirli ülkelerde enfeksiyon yükünü azaltmada en önemli yöntemlerden biridir. Bu makalede HPV aşılarında stratejiler, koruyuculuk ve muhtemel yan etkiler ele alınmaktadır.

Keywords

HPV, HPV aşısı, serviks kanseri, koruyuculuk, yan etkiler

Current approaches to HPV (Human papillomavirus) vaccine

Abstract

Human papillomavirus (HPV) infection is considered as the most common viral sexually transmitted infection worldwide. HPV infection causes common and anogenital warts, as well as other non-dermatological diseases. The association between certain oncogenic (high-risk) strains of HPV and cervical cancer is well established. The HPV vaccine offers a long-lasting, reliable defence against the HPV infection that is most frequently linked to cancer. Also, HPV vaccination reduces the risk of developing cancers caused by HPV at sites other than the cervix. Vaccines work by preventing infections prior to natural exposure so HPV vaccination prior to onset of sexual activity is recommended to maximize the benefit of the vaccine. Providing education about HPV and vaccination is one of the most important issues that decreases the burden of the infection especially in low and middle income countries. This article will discuss the vaccination strategies, protectivity and possible side effects of HPV vaccination.

Keywords

HPV, HPV vaccine, cervix cancer, protectivity, side effects

References

• Milano G, Guarducci G, Nante N, Montomoli E, Manini I. Human papillomavirus epidemiology and prevention: is there still a gender gap? Vaccines (Basel). 2023;11:1060.
• Cubie HA. Diseases associated with human papillomavirus infection. Virology. 2013;445:21-34.
• Xu J, Abudurusuli G, Rui J, et al. Epidemiological characteristics and transmissibility of HPV infection: A long-term retrospective study in Hokkien Golden Triangle, China, 2013-2021. Epidemics. 2023;44:100707.
• Alrefai EA, Alhejaili RT, Haddad SA. Human papillomavirus and its association with cervical cancer: a review. Cureus. 2024;16:e57432.
• Waheed DE, Bolio A, Guillaume D et al. Planning, implementation, and sustaining high coverage of human papillomavirus (HPV) vaccination programs: What works in the context of low-resource countries?. Front Public Health. 2023;11:1112981.
• Ljubojevic S, Skerlev M. HPV-associated diseases. Clin Dermatol. 2014;32:227-34.
• Medda A, Duca D, Chiocca S. Human papillomavirus and cellular pathways: hits and targets. Pathogens. 2021;10:262.
• Ozgul N, Tuncer M, Abacioglu M, Gultekin M. Estimating prevalence of genital warts in Turkey: survey among KETEM-affiliated gynecologists across Turkey. Asian Pac J Cancer Prev. 2011;12:2397-2400.
• Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet. 2019;393:169-182.
• Hantz S, Alain S, Denis F. Human papillomavirus prophylactic vaccines: stakes and perspectives. Gynecol Obstet Fertil. 2006;34:647-55.
• Ashique S, Hussain A, Fatima N, Altamimi MA. HPV pathogenesis, various types of vaccines, safety concern, prophylactic and therapeutic applications to control cervical cancer, and future perspective. Virusdisease. 2023;34:1-19.
• Kelly BJ, Leader AE, Mittermaier DJ, Hornik RC, Cappella JN. The HPV vaccine and the media: how has the topic been covered and what are the effects on knowledge about the virus and cervical cancer?. Patient Educ Couns. 2009;77:308-13.
• Schmiedeskamp MR, Kockler DR. Human papillomavirus vaccines. Ann Pharmacother. 2006;40:1344-52.
• Rouzier R, Uzan C, Collinet P. HPV vaccination: principles, results and future perspectives. J Gynecol Obstet Biol Reprod (Paris). 2007;36:13-8.
• Gonçalves AK, Cobucci RN, Rodrigues HM, de Melo AG, Giraldo PC. Safety, tolerability and side effects of human papillomavirus vaccines: a systematic quantitative review. Braz J Infect Dis. 2014;18:651-59.
• Siddiqui AA, Zain Ul Abideen M, Fatima S, et al. Students' perception of online versus face-to-face learning: what do the healthcare teachers have to know? Cureus. 2024;16:e54217.
• Garland SM, Kjaer SK, Muñoz N, Block SL, Brown DR, DiNubile MJ et al.. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clin Infect Dis. 2016;63:519-27.
• Chilaka VN, Navti OB, Al Beloushi M, Ahmed B, Konje JC. Human papillomavirus (HPV) in pregnancy - An update. Eur J Obstet Gynecol Reprod Biol. 2021;264:340-8.
• Yu W, Hu X, Cao B. viral infections during pregnancy: the big challenge threatening maternal and fetal health. Matern Fetal Med. 2021;4:72-86.
• López-Fauqued M, Zima J, Angelo MG, Stegmann JU. Results on exposure during pregnancy from a pregnancy registry for AS04-HPV-16/18 vaccine. Vaccine. 2017;35:5325-30.